Core Insights - Artelo Biosciences, Inc. has announced a private placement for the purchase and sale of 3,188,407 shares of common stock and warrants to purchase up to 6,376,814 shares at a price of $3.45 per share, with the transaction expected to close around March 30, 2026 [1][2] Group 1: Financial Details - The gross proceeds from the offering are anticipated to be approximately $11.0 million before deducting fees and expenses [2] - If the warrants are fully exercised, the potential additional gross proceeds could reach approximately $20.4 million [2] Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for working capital, general corporate purposes, and repayment of certain bridge debt [2] Group 3: Securities Offering - The securities are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933 and have not been registered under the Securities Act or applicable state laws [3] - The company has agreed to file a resale registration statement covering the securities as part of a registration rights agreement with investors [3] Group 4: Company Overview - Artelo Biosciences is a clinical-stage pharmaceutical company focused on developing therapeutics that modulate lipid-signaling pathways, addressing unmet needs in various medical conditions [5]

Company Overview - Multitude Capital Oyj acts as the funding vehicle for Multitude Group, issuing bonds to support liquidity for the Group's operations [3] - Multitude AG is a listed European FinTech company providing digital lending and online banking services to consumers, SMEs, and institutional clients, operating through three independent business units: Consumer Banking (Ferratum), SME Banking (CapitalBox), and Wholesale Banking (Multitude Bank) [4] - The Group employs over 700 people and offers services in 17 European countries [4] Financial Highlights - In 2025, Multitude Group achieved a revenue of EUR 257 million [4] - As of 20 March 2026, the Company and the Parent held Capital Notes in an aggregated nominal amount of EUR 27,678,000 [1] - Following a recent repurchase, the total nominal amount of Capital Notes held by the Company and the Parent increased to EUR 32,428,000, with EUR 27,428,000 held by the Company and EUR 5,000,000 held by the Parent [2]

Core Viewpoint - Afarak Group SE has published its Annual Financial Report for the year 2025, including the Board of Directors report, Financial Statement, Auditor's Report, and Corporate Governance Statement, available on the company's website [1][2]. Group 1: Financial Reporting - The Financial Statements are published in accordance with European Single Electronic Format (ESEF) reporting requirements, utilizing XHTML format with XBRL tags [1]. - A copy of the Board of Directors report and Financial Statements for 2025 has been submitted to the UK's National Storage Mechanism [2]. Group 2: Corporate Governance - The company will hold its 2026 Annual General Meeting in Helsinki, complying with the Finnish Companies Act [2]. - The Corporate Governance Statement for 2025 is included in the published documents [1][3]. Group 3: Company Overview - Afarak Group is a specialist alloy producer focused on sustainable growth, with operations in Specialty Alloys in southern Europe and FerroAlloys in South Africa [3]. - The company is listed on NASDAQ Helsinki (AFAGR) and the Main Market of the London Stock Exchange (AFRK) [3].

Performance Overview - Volta Finance reported a net return of -3% for February 2026, underperforming compared to US High Yield bonds (+0.2%) and Euro High Yield bonds (+0.3%) [4] - The company's NAV at the end of February 2026 was €248.5 million, equating to €6.79 per share [10] Market Context - The month began with President Trump's announcement of an increase in the baseline import tariff rate from 10% to 15%, which shifted focus to artificial intelligence and its disruption risks [5] - Credit markets experienced a significant revaluation of risk, particularly in direct lending, leading to increased redemption requests and activation of redemption gates by some managers [5] CLO and Loan Market Activity - Loans and CLOs faced notable spread repricing due to their historical concentration in the software industry, with Euro Loans declining approximately 0.7 points and US Loans falling by more than one point [6] - CLO Primary markets saw a winding down as volatility increased, while secondary markets experienced significant repricing across all tranches, particularly impacting junior tranches [6] Trading and Investment Activity - The company reset one of its amortizing US CLO positions, requiring around USD 4 million of additional equity, resulting in a debt cost reduction of approximately 130 bps [8] - Trading activity included purchases of EUR BBs and single-B tranches within a spread range of +[860-950] bps, and a controlling EUR equity tranche was acquired for EUR 5.6 million [9] Economic and Geopolitical Factors - The end of February was marked by a new conflict in Iran, causing sharp declines in Treasuries and surges in oil prices, raising concerns about global oil supply disruptions and inflation [7] - Persistent oil price increases may impact economic growth and delay anticipated rate reductions from central banks, adding pressure on credit markets [7]

Core Insights - Palvella Therapeutics is focused on developing innovative therapies for serious, rare skin diseases and vascular malformations, with a commitment to addressing unmet medical needs in this area [1][9] Group 1: QTORIN™ Rapamycin Development - QTORIN™ rapamycin is a single-phase anhydrous gel designed to enhance dermal bioavailability and overcome challenges related to crystallization and stability of rapamycin [1][2] - The Phase 3 SELVA study demonstrated that QTORIN™ rapamycin met its primary endpoint with statistically significant improvement in the Microcystic Lymphatic Malformation Investigator Global Assessment (mLM-IGA) (p<0.001) [4] - QTORIN™ rapamycin is being developed for multiple conditions, including microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas, with a fourth indication expected to be announced in the second half of 2026 [5][9] Group 2: Porokeratosis Research - A qualitative study highlighted the significant burden of living with porokeratosis, a rare genetic skin disease with no FDA-approved therapies, emphasizing its physical, psychosocial, and cancer-related impacts [2][12] - The study involved ten in-depth interviews with patients and caregivers, revealing challenges such as social isolation, anxiety, and limitations in daily activities due to the disease [12] - Palvella is also developing QTORIN™ pitavastatin for disseminated superficial actinic porokeratosis, with a Phase 2 trial anticipated to begin in the second half of 2026 [8]

Core Insights - Aclaris Therapeutics has reported positive results from its Phase 2a trial of ATI-2138, an investigational oral covalent inhibitor targeting ITK and JAK3, showing significant improvements in patients with moderate-to-severe atopic dermatitis [1][2][4] Group 1: Clinical Trial Results - Patients receiving a low dose (10 mg BID) of ATI-2138 experienced a 77% improvement in the extent and severity of atopic dermatitis as measured by the Eczema Area and Severity Index (EASI) at the end of treatment (week 12) [4] - Additional improvements included a 70% reduction in the affected percentage of Body Surface Area (BSA), a 50% improvement in Peak Pruritus Numerical Rating Scale (PP-NRS), a 55% improvement in patient-oriented eczema measure (POEM), and a 65% improvement in Dermatology Life Quality Index (DLQI) [6] Group 2: Mechanism and Efficacy - ATI-2138 demonstrated near complete and sustained ITK target occupancy, indicating its high potency and potential for low drug burden and improved tolerability compared to existing JAK inhibitors [4][5] - The compound modulated various immune signaling pathway markers, supporting its broad therapeutic potential in treating immuno-inflammatory diseases [4][7] Group 3: Company Overview - Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, aiming to address unmet medical needs [8]

Core Viewpoint - The Urbo Bankas UAB held its Ordinary General Meeting of Shareholders on March 27, 2026, where significant decisions were made regarding the bank's operations and governance [1]. Group 1: Meeting Outcomes - The resolutions adopted during the meeting are documented and attached for review [1]. - The profit allocation for the year 2025 has been outlined in the attached documents [1]. - A new version of the Urbo Bank's Articles of Association has been approved and is included in the attachments [1].

Core Insights - Dangbei is promoting a week-long event on Amazon.ca, offering discounts of up to 39.5% on six different projectors, encouraging Canadians to consider projectors over traditional TVs this spring [3][4]. Product Offerings - **Dangbei N2 mini**: Priced at CA$199 (originally CA$329), it features native 1080p resolution, built-in Netflix and YouTube, and can project images from 40 to 120 inches [5]. - **Dangbei Freedo**: Now CA$549 (was CA$789), this portable projector has a built-in battery lasting approximately 2.5 hours, delivering 1080p resolution at 450 ISO lumens [6]. - **Dangbei Atom**: Available for CA$749 (originally CA$999), it is a slim projector that uses ALPD laser technology to project up to 180 inches in 1080p [7][8]. - **Dangbei DBOX02**: Priced at CA$1,349 (was CA$1,999), it offers 2,450 ISO lumens and projects up to 200 inches in native 4K [9]. - **Dangbei DBOX02 Pro**: Now CA$1,349 (previously CA$1,599), it features enhanced tone mapping and 2,000 ISO lumens, suitable for various room layouts [10]. - **Dangbei MP1 Max**: Priced at CA$1,979 (was CA$2,199), it boasts 3,100 ISO lumens and supports HDR10+ and Blu-ray 3D, targeting home cinema enthusiasts [11]. Market Context - The promotion highlights a shift in Canadian entertainment consumption, with an increase in streaming subscriptions and a trend towards portable and versatile viewing options [4][12]. - The cost of a 75-inch TV in Canada typically ranges from CA$1,500 to CA$3,000, while Dangbei projectors offer larger screens at similar or lower prices, appealing to consumers with limited space [12][13]. Shopping Information - The promotion runs from March 27 to March 31, 2026, with all deals available on the Dangbei Amazon.ca Store, ensuring standard Canadian delivery options and adherence to Amazon's return policy [14]. Company Overview - Dangbei is a premium smart entertainment company specializing in home and portable projectors, trusted by over 200 million users globally, and known for its advanced projection technologies [15].

Core Insights - Dangbei is launching a Spring Promotion from March 27 to March 31, 2026, offering discounts of up to 47% on selected 4K home cinema and portable projectors on Amazon US [1][19] Product Offerings - The Dangbei DBOX02 Pro is a 4K laser projector featuring a flexible gimbal stand, 2000 ISO lumens brightness, and enhanced tone mapping, priced at $899 after a 43.8% discount from $1,599 [4][5] - The Dangbei DBOX02, a 4K ALPD laser projector, offers up to 2450 ISO lumens and built-in Google TV and Netflix, now available for $999, reflecting a 47.4% discount from $1,899 [7][8] - The Dangbei MP1 Max, a hybrid tri-laser + LED projector, delivers 3100 ISO lumens and is priced at $1,299 after a 35% discount from $1,999 [10][11] - The Dangbei Freedo is a portable 1080p projector with a built-in battery, offering 450 ISO lumens and priced at $319, down 41.9% from $549 [13][14] - The Dangbei Atom is an ultra-slim laser projector with 1080p resolution and 1200 ISO lumens, now available for $549 after a 38.9% discount from $899 [16][17] - The Dangbei N2 Mini is a compact 1080p projector designed for small spaces, priced at $149 after a 34.9% discount from $229 [18][19] Company Overview - Dangbei is a premium provider of smart entertainment solutions, specializing in home and portable projectors, with over 200 million users globally [19]

Group 1 - The annual report and audit report for Virtune AB (Publ) for the financial year 2025 are now available [1] - Reports can be accessed via the attached PDF or the company's website [1]